Navigation Links
Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials
Date:7/22/2014

mF0aW9uYWwv" title="Quorum's International Ethics Review" class="trackingLink" rel="nofollow" trackingLink="http://www.quorumreview.com/international/" >international country selection. Quorum can populate the client’s submission forms and ensure they are taking full advantage of all efficiencies and customizations available to them.

Additional opportunities for customization and efficiency include custom document citations, consent form development, recruitment material processing prior to initial Board review, and complimentary tracking of amendment language into the consent form. Quick Step™ customers have access to research sites from Quorum’s Site Directory and assistance in outreach to potential sites. Quorum’s Outreach Program has been particularly successful at enrolling high numbers of Institutional sites with Quorum as the central IRB. Once Quick Step™ studies are in-house they are prioritized, and turnaround times are measured and reported to the respective client.

Quorum’s CEO Cami Gearhart says of the new service, “Quorum is very excited to offer this new suite of services that will make running these complex and important large clinical studies streamlined and simple.”

For more details on Quorum Review’s new Quick Step™ service, visit http://www.quorumreview.com/quickstep.

About Quorum Review IRB

Quorum Review is an independent institutional review board fully accredited by the Association for the Accreditation of Huma
'/>"/>

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Quorum IRB Board Chair to Speak at South Korean Research Summit
2. Quorum Review’s Mitchell Parrish Presents at Embracing Change: Clinical Research in the 21st Century
3. Quorum Review IRB and ConsentSolutions Form Strategic Alliance
4. Quorum Review IRB Board Chair Appointed to SACHRP
5. A Critical Review of Analytical Techniques for Improved Living Standards
6. Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board
7. Gordon Hunter’s ‘How Are You, Mother Earth?’ Receives Four Stars from Clarion Review
8. A Review of Cardiovascular Pressure Sensing and Relevant Performance Specifications to Ensure Data Integrity, a New and Upcoming Webinar Hosted by Xtalks
9. Scar Global Clinical Trials Review, H2, 2013
10. Acute Pain Global Clinical Trials Review, H2, 2013
11. Barretts Esophagus Global Clinical Trials Review, H2, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 2015  CytRx Corporation (NASDAQ: CYTR ), ... oncology, today announced positive updated results from its ... the treatment of unresectable glioblastoma multiforme (GBM), a ... trial is designed to investigate the preliminary efficacy ... have progressed following prior treatment with surgery, radiation ...
(Date:5/21/2015)... , May 21, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company focused on the development ... poster presentation at the International Society for Cellular ... chronic Achilles tendinosis currently in a Phase 1/2 ... 29 th from 5:30 PM to 7:00 ...
(Date:5/20/2015)... SAN FRANCISCO, Calif. , May 20, 2015 ... VCYT ) today presented preliminary data demonstrating the ... distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial ... The findings suggest the classifier,s potential to help ... surgery to resolve ambiguity in IPF diagnosis – ...
(Date:5/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) has ... Market Outlook 2020 " report to their offering. ... regenerative medicine is expected to have huge marketing potential. ... in the growth of deregulated organs. Several therapeutic molecules ... to form new tissue or sometimes organ transplant is ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
... SOUTH SAN FRANCISCO, Calif., Oct. 27 Monogram,Biosciences, Inc., ... of,Directors has approved a 6-to-1 reverse split of its ... stockholders at the,September 19, 2007 annual meeting. The Company,s ... on November 4, 2008, under the temporary,trading symbol "MGRMD" ...
... Beckman,Coulter, Inc. (NYSE: BEC ), a ... simplify, automate, and innovate complex biomedical,testing, announced ... and chief executive officer, will present at ... 4, 2008 at 1:20 p.m.,(ET)., (Logo: ...
... 27 Cepheid (Nasdaq:,CPHD) today noted an announcement ... MRSA test, which runs on the,GeneXpert(R) System, to ... to its Intensive Care Unit (ICU)., The ... an accurate and rapid result for MRSA is ...
Cached Biology Technology:Monogram Announces a 6-to-1 Reverse Stock Split 2Monogram Announces a 6-to-1 Reverse Stock Split 3Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing 2Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing 3Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing 4
(Date:4/14/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® smart ... Design Awards under the category  ,Product Design – Technology,. ... are part of a global multi-disciplinary awards program. The ... marketplace, industry and judging panel. Winners will be announced ...
(Date:4/13/2015)... , April 13, 2015  higi, a leading cloud-based ... to more fully engage with their communities around health ... privacy protected and secure API.  ... the most accessible, affordable, and convenient vehicle to receive ... The API will allow higi,s ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... 23, 2015, after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2
... results in fighting a severe genetic disorder which can create ... transformed our understanding of disease in recent years. We now ... conditions. However, so far, very few cures and treatments have ... UK study led by researchers at Cardiff University suggests that ...
... are Expanding eDirectory Applications and, Technology in ... SUNNYVALE, Calif., Jan. 9 Ingram Micro Inc.,(NYSE: ... has signed an,agreement with Fujitsu Microelectronics America, Inc. ... for Novell(R) eDirectory(TM),and Novell Access Manager. The contract ...
... stars have understudies. Now, an increasingly popular radioactive ... by researchers at the National Institute of Standards ... medical imaging, speed up clinical trials of many ... medical treatment. The number of medical images ...
Cached Biology News:Genetic breakthrough offers promise in tackling kidney tumors 2Ingram Micro to Distribute New Fujitsu Biometric Login Products for Novell eDirectory in United States 2Ingram Micro to Distribute New Fujitsu Biometric Login Products for Novell eDirectory in United States 3Radioactive 'understudy' may aid medical imaging, drug development 2
Anti-Digoxigenin-AP, Fab fragments; from sheep...
The antibody recognizes the peptide sequence ESESQGPK (aa 441-448) of human class III beta-tubulin specific for neurones....
Unique enzyme blend containing Taq and Pwo DNA Polymerase and another thermostable enzyme. The Expand 20 kbPLUS PCR System also includes an optimized reaction buffer, MgCl2 solution, and a human cont...
... This antibody is generated from rabbits immunized ... within aa 50~150 of human PLAU. Purified ... 0.09% (W/V) sodium azide. This antibody is ... eluted out with both high and low ...
Biology Products: